st james's oncology spc ltd
st james's oncology spc ltd Company Information
Company Number
05113572
Next Accounts
Sep 2025
Shareholders
st james's oncology spc holdings ltd
Group Structure
View All
Industry
Other human health activities
Registered Address
c/o albany spc services ltd, 3rd floor, manchester, M1 4HB
Website
lendlease.comst james's oncology spc ltd Estimated Valuation
Pomanda estimates the enterprise value of ST JAMES'S ONCOLOGY SPC LTD at £25.5m based on a Turnover of £31.7m and 0.8x industry multiple (adjusted for size and gross margin).
st james's oncology spc ltd Estimated Valuation
Pomanda estimates the enterprise value of ST JAMES'S ONCOLOGY SPC LTD at £48.4m based on an EBITDA of £7.8m and a 6.2x industry multiple (adjusted for size and gross margin).
st james's oncology spc ltd Estimated Valuation
Pomanda estimates the enterprise value of ST JAMES'S ONCOLOGY SPC LTD at £0 based on Net Assets of £-4.9m and 2.35x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
St James's Oncology Spc Ltd Overview
St James's Oncology Spc Ltd is a live company located in manchester, M1 4HB with a Companies House number of 05113572. It operates in the other human health activities sector, SIC Code 86900. Founded in April 2004, it's largest shareholder is st james's oncology spc holdings ltd with a 100% stake. St James's Oncology Spc Ltd is a mature, large sized company, Pomanda has estimated its turnover at £31.7m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
St James's Oncology Spc Ltd Health Check
Pomanda's financial health check has awarded St James'S Oncology Spc Ltd a 4 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 3 areas for improvement. Company Health Check FAQs
5 Strong
2 Regular
3 Weak
Size
annual sales of £31.7m, make it larger than the average company (£798.1k)
£31.7m - St James's Oncology Spc Ltd
£798.1k - Industry AVG
Growth
3 year (CAGR) sales growth of 13%, show it is growing at a faster rate (6.5%)
13% - St James's Oncology Spc Ltd
6.5% - Industry AVG
Production
with a gross margin of 30.7%, this company has a comparable cost of product (36.5%)
30.7% - St James's Oncology Spc Ltd
36.5% - Industry AVG
Profitability
an operating margin of 24.6% make it more profitable than the average company (5.6%)
24.6% - St James's Oncology Spc Ltd
5.6% - Industry AVG
Employees
with 616 employees, this is above the industry average (19)
- St James's Oncology Spc Ltd
19 - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- St James's Oncology Spc Ltd
- - Industry AVG
Efficiency
resulting in sales per employee of £51.5k, this is equally as efficient (£51.5k)
- St James's Oncology Spc Ltd
£51.5k - Industry AVG
Debtor Days
it gets paid by customers after 0 days, this is earlier than average (22 days)
0 days - St James's Oncology Spc Ltd
22 days - Industry AVG
Creditor Days
its suppliers are paid after 0 days, this is quicker than average (17 days)
0 days - St James's Oncology Spc Ltd
17 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - St James's Oncology Spc Ltd
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 42 weeks, this is less cash available to meet short term requirements (101 weeks)
42 weeks - St James's Oncology Spc Ltd
101 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 101.8%, this is a higher level of debt than the average (27.9%)
101.8% - St James's Oncology Spc Ltd
27.9% - Industry AVG
ST JAMES'S ONCOLOGY SPC LTD financials
St James'S Oncology Spc Ltd's latest turnover from December 2023 is £31.7 million and the company has net assets of -£4.9 million. According to their latest financial statements, we estimate that St James'S Oncology Spc Ltd has 616 employees and maintains cash reserves of £17 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 31,711,000 | 31,876,000 | 24,114,000 | 21,806,000 | 27,321,000 | 20,816,000 | 21,412,000 | 18,936,000 | 18,136,000 | 17,674,000 | 17,246,000 | 15,242,000 | 13,450,000 | 14,516,000 | 10,781,000 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 21,977,000 | 21,311,000 | 16,075,000 | 14,296,000 | 19,771,000 | 13,313,000 | 13,744,000 | 12,852,000 | 11,667,000 | 10,660,000 | |||||
| Gross Profit | 9,734,000 | 10,565,000 | 8,039,000 | 7,510,000 | 7,550,000 | 7,503,000 | 7,668,000 | 6,084,000 | 6,469,000 | 7,014,000 | |||||
| Admin Expenses | 1,929,000 | 2,115,000 | 2,817,000 | 2,333,000 | 1,620,000 | 2,017,000 | 4,653,000 | 1,253,000 | 1,189,000 | 2,350,000 | |||||
| Operating Profit | 7,805,000 | 8,450,000 | 5,222,000 | 5,177,000 | 5,930,000 | 5,486,000 | 3,015,000 | 4,831,000 | 5,280,000 | 4,664,000 | 4,005,000 | 3,752,000 | 3,825,000 | 3,209,000 | 2,532,000 |
| Interest Payable | 14,734,000 | 16,637,000 | 13,915,000 | 12,310,000 | 12,626,000 | 12,787,000 | 12,992,000 | 14,338,000 | 14,700,000 | 13,983,000 | 14,186,000 | 14,317,000 | 14,309,000 | 14,410,000 | 14,501,000 |
| Interest Receivable | 10,826,000 | 9,960,000 | 10,493,000 | 10,912,000 | 10,821,000 | 10,578,000 | 10,331,000 | 12,702,000 | 12,995,000 | 13,229,000 | 13,693,000 | 13,853,000 | 13,841,000 | 13,818,000 | 13,877,000 |
| Pre-Tax Profit | 3,897,000 | 1,773,000 | 1,800,000 | 3,779,000 | 4,125,000 | 3,277,000 | 354,000 | 3,195,000 | 3,575,000 | 3,910,000 | 3,512,000 | 3,288,000 | 3,357,000 | 2,617,000 | 1,908,000 |
| Tax | 563,000 | -1,205,000 | -1,301,000 | -787,000 | -621,000 | 22,000 | -167,000 | -582,000 | -627,000 | -883,000 | -856,000 | -736,000 | -759,000 | -526,000 | -447,000 |
| Profit After Tax | 4,460,000 | 568,000 | 499,000 | 2,992,000 | 3,504,000 | 3,299,000 | 187,000 | 2,613,000 | 2,948,000 | 3,027,000 | 2,656,000 | 2,552,000 | 2,598,000 | 2,091,000 | 1,461,000 |
| Dividends Paid | 601,000 | ||||||||||||||
| Retained Profit | 4,460,000 | 568,000 | 499,000 | 2,992,000 | 3,504,000 | 3,299,000 | 187,000 | 2,613,000 | 2,948,000 | 3,027,000 | 2,656,000 | 2,552,000 | 2,598,000 | 1,490,000 | 1,461,000 |
| Employee Costs | 155,000 | ||||||||||||||
| Number Of Employees | 57 | ||||||||||||||
| EBITDA* | 7,805,000 | 8,450,000 | 5,222,000 | 5,177,000 | 5,930,000 | 5,486,000 | 3,015,000 | 4,831,000 | 5,280,000 | 4,664,000 | 4,005,000 | 3,752,000 | 3,825,000 | 3,209,000 | 2,532,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | |||||||||||||||
| Intangible Assets | |||||||||||||||
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | 222,849,000 | 233,905,000 | 228,876,000 | 243,920,000 | 207,347,000 | 203,173,000 | 207,421,000 | 187,084,000 | 189,849,000 | 188,271,000 | 191,763,000 | 193,944,000 | 196,517,000 | 200,010,000 | 201,397,000 |
| Total Fixed Assets | 222,849,000 | 233,905,000 | 228,876,000 | 243,920,000 | 207,347,000 | 203,173,000 | 207,421,000 | 187,084,000 | 189,849,000 | 188,271,000 | 191,763,000 | 193,944,000 | 196,517,000 | 200,010,000 | 201,397,000 |
| Stock & work in progress | |||||||||||||||
| Trade Debtors | 3,000 | 1,427,000 | 193,000 | 229,000 | 22,000 | 242,000 | 263,000 | 569,000 | 5,479,000 | 277,000 | 308,000 | 259,000 | 290,000 | 370,000 | 5,000 |
| Group Debtors | |||||||||||||||
| Misc Debtors | 13,583,000 | 8,819,000 | 14,839,000 | 14,455,000 | 49,521,000 | 44,012,000 | 38,947,000 | 32,127,000 | 24,385,000 | 32,562,000 | 22,534,000 | 19,423,000 | 16,448,000 | 12,996,000 | 9,963,000 |
| Cash | 17,018,000 | 38,156,000 | 25,371,000 | 21,405,000 | 14,488,000 | 32,512,000 | 33,912,000 | 35,913,000 | 32,779,000 | 31,953,000 | 33,245,000 | 29,230,000 | 25,600,000 | 22,586,000 | 23,148,000 |
| misc current assets | 16,820,000 | 11,200,000 | 9,320,000 | 14,780,000 | |||||||||||
| total current assets | 47,424,000 | 48,402,000 | 51,603,000 | 45,409,000 | 78,811,000 | 76,766,000 | 73,122,000 | 68,609,000 | 62,643,000 | 64,792,000 | 56,087,000 | 48,912,000 | 42,338,000 | 35,952,000 | 33,116,000 |
| total assets | 270,273,000 | 282,307,000 | 280,479,000 | 289,329,000 | 286,158,000 | 279,939,000 | 280,543,000 | 255,693,000 | 252,492,000 | 253,063,000 | 247,850,000 | 242,856,000 | 238,855,000 | 235,962,000 | 234,513,000 |
| Bank overdraft | 6,391,000 | ||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 18,000 | 2,993,000 | 49,000 | 249,000 | 1,218,000 | 1,002,000 | 1,000,000 | 2,643,000 | 249,000 | 1,552,000 | 4,548,000 | 250,000 | 280,000 | 1,561,000 | 45,000 |
| Group/Directors Accounts | 13,219,000 | 13,949,000 | 13,537,000 | 15,386,000 | 17,924,000 | 12,834,000 | 11,143,000 | 1,158,000 | 1,576,000 | 1,391,000 | 1,175,000 | 1,618,000 | 884,000 | 746,000 | 1,590,000 |
| other short term finances | 4,721,000 | 8,467,000 | 2,190,000 | 6,356,000 | 3,545,000 | 2,978,000 | 2,352,000 | 1,611,000 | 1,426,000 | 1,216,000 | |||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 3,004,000 | 1,240,000 | 3,609,000 | 2,617,000 | 1,505,000 | 2,683,000 | 2,452,000 | 3,132,000 | 4,658,000 | 7,608,000 | 5,471,000 | 6,557,000 | 5,925,000 | 4,779,000 | 6,170,000 |
| total current liabilities | 20,962,000 | 26,649,000 | 19,385,000 | 18,252,000 | 20,647,000 | 16,519,000 | 14,595,000 | 13,324,000 | 12,839,000 | 14,096,000 | 14,172,000 | 10,777,000 | 8,700,000 | 8,512,000 | 9,021,000 |
| loans | 236,719,000 | 247,964,000 | 251,098,000 | 247,867,000 | 251,649,000 | 262,434,000 | 270,995,000 | 199,894,000 | 235,541,000 | 207,141,000 | 211,291,000 | 213,709,000 | 216,174,000 | 217,895,000 | 219,520,000 |
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | 43,340,000 | 38,094,000 | |||||||||||||
| provisions | 17,450,000 | 19,987,000 | 16,086,000 | 17,239,000 | 16,965,000 | 16,302,000 | 17,094,000 | 15,695,000 | 13,962,000 | 11,359,000 | 11,397,000 | 10,036,000 | 8,199,000 | 6,371,000 | 4,278,000 |
| total long term liabilities | 254,169,000 | 267,951,000 | 267,184,000 | 265,106,000 | 268,614,000 | 278,736,000 | 288,089,000 | 258,929,000 | 249,503,000 | 256,594,000 | 222,688,000 | 223,745,000 | 224,373,000 | 224,266,000 | 223,798,000 |
| total liabilities | 275,131,000 | 294,600,000 | 286,569,000 | 283,358,000 | 289,261,000 | 295,255,000 | 302,684,000 | 272,253,000 | 262,342,000 | 270,690,000 | 236,860,000 | 234,522,000 | 233,073,000 | 232,778,000 | 232,819,000 |
| net assets | -4,858,000 | -12,293,000 | -6,090,000 | 5,971,000 | -3,103,000 | -15,316,000 | -22,141,000 | -16,560,000 | -9,850,000 | -17,627,000 | 10,990,000 | 8,334,000 | 5,782,000 | 3,184,000 | 1,694,000 |
| total shareholders funds | -4,858,000 | -12,293,000 | -6,090,000 | 5,971,000 | -3,103,000 | -15,316,000 | -22,141,000 | -16,560,000 | -9,850,000 | -17,627,000 | 10,990,000 | 8,334,000 | 5,782,000 | 3,184,000 | 1,694,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 7,805,000 | 8,450,000 | 5,222,000 | 5,177,000 | 5,930,000 | 5,486,000 | 3,015,000 | 4,831,000 | 5,280,000 | 4,664,000 | 4,005,000 | 3,752,000 | 3,825,000 | 3,209,000 | 2,532,000 |
| Depreciation | |||||||||||||||
| Amortisation | |||||||||||||||
| Tax | 563,000 | -1,205,000 | -1,301,000 | -787,000 | -621,000 | 22,000 | -167,000 | -582,000 | -627,000 | -883,000 | -856,000 | -736,000 | -759,000 | -526,000 | -447,000 |
| Stock | |||||||||||||||
| Debtors | -7,716,000 | 243,000 | -14,696,000 | 1,714,000 | 9,463,000 | 796,000 | 26,851,000 | 67,000 | -1,397,000 | 6,505,000 | 979,000 | 371,000 | -121,000 | 2,011,000 | 211,365,000 |
| Creditors | -2,975,000 | 2,944,000 | -200,000 | -969,000 | 216,000 | 2,000 | -1,643,000 | 2,394,000 | -1,303,000 | -2,996,000 | 4,298,000 | -30,000 | -1,281,000 | 1,516,000 | 45,000 |
| Accruals and Deferred Income | 1,764,000 | -2,369,000 | 992,000 | 1,112,000 | -1,178,000 | 231,000 | -680,000 | -1,526,000 | -2,950,000 | 2,137,000 | -1,086,000 | 632,000 | 1,146,000 | -1,391,000 | 6,170,000 |
| Deferred Taxes & Provisions | -2,537,000 | 3,901,000 | -1,153,000 | 274,000 | 663,000 | -792,000 | 1,399,000 | 1,733,000 | 2,603,000 | -38,000 | 1,361,000 | 1,837,000 | 1,828,000 | 2,093,000 | 4,278,000 |
| Cash flow from operations | 12,336,000 | 11,478,000 | 18,256,000 | 3,093,000 | -4,453,000 | 4,153,000 | -24,927,000 | 6,783,000 | 4,400,000 | -3,621,000 | 6,743,000 | 5,084,000 | 4,880,000 | 2,890,000 | -198,787,000 |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | -730,000 | 412,000 | -1,849,000 | -2,538,000 | 5,090,000 | 1,691,000 | 9,985,000 | -418,000 | 185,000 | 216,000 | -443,000 | 734,000 | 138,000 | -844,000 | 1,590,000 |
| Other Short Term Loans | -3,746,000 | 6,277,000 | 2,190,000 | -6,356,000 | 2,811,000 | 567,000 | 626,000 | 741,000 | 185,000 | 210,000 | 1,216,000 | ||||
| Long term loans | -11,245,000 | -3,134,000 | 3,231,000 | -3,782,000 | -10,785,000 | -8,561,000 | 71,101,000 | -35,647,000 | 28,400,000 | -4,150,000 | -2,418,000 | -2,465,000 | -1,721,000 | -1,625,000 | 219,520,000 |
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | -43,340,000 | 43,340,000 | -38,094,000 | 38,094,000 | |||||||||||
| share issue | |||||||||||||||
| interest | -3,908,000 | -6,677,000 | -3,422,000 | -1,398,000 | -1,805,000 | -2,209,000 | -2,661,000 | -1,636,000 | -1,705,000 | -754,000 | -493,000 | -464,000 | -468,000 | -592,000 | -624,000 |
| cash flow from financing | -16,654,000 | -9,893,000 | -12,410,000 | -1,636,000 | 1,209,000 | -5,553,000 | 29,317,000 | -10,040,000 | -3,574,000 | 2,329,000 | -2,728,000 | -1,454,000 | -1,866,000 | -2,851,000 | 221,935,000 |
| cash and cash equivalents | |||||||||||||||
| cash | -21,138,000 | 12,785,000 | 3,966,000 | 6,917,000 | -18,024,000 | -1,400,000 | -2,001,000 | 3,134,000 | 826,000 | -1,292,000 | 4,015,000 | 3,630,000 | 3,014,000 | -562,000 | 23,148,000 |
| overdraft | -6,391,000 | 6,391,000 | |||||||||||||
| change in cash | -21,138,000 | 12,785,000 | 3,966,000 | 6,917,000 | -18,024,000 | -1,400,000 | 4,390,000 | -3,257,000 | 826,000 | -1,292,000 | 4,015,000 | 3,630,000 | 3,014,000 | -562,000 | 23,148,000 |
st james's oncology spc ltd Credit Report and Business Information
St James's Oncology Spc Ltd Competitor Analysis
Perform a competitor analysis for st james's oncology spc ltd by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other large companies, companies in M 1 area or any other competitors across 12 key performance metrics.
st james's oncology spc ltd Ownership
ST JAMES'S ONCOLOGY SPC LTD group structure
St James'S Oncology Spc Ltd has no subsidiary companies.
Ultimate parent company
2 parents
ST JAMES'S ONCOLOGY SPC LTD
05113572
st james's oncology spc ltd directors
St James'S Oncology Spc Ltd currently has 6 directors. The longest serving directors include Mr Christopher Solley (Oct 2012) and Mr Barry Millsom (Sep 2014).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Christopher Solley | England | 54 years | Oct 2012 | - | Director |
| Mr Barry Millsom | England | 50 years | Sep 2014 | - | Director |
| Mr Michael Williams | England | 45 years | Jan 2021 | - | Director |
| Mr Johan Potgieter | England | 44 years | Jan 2021 | - | Director |
| Mr Johan Potgieter | United Kingdom | 44 years | Jan 2021 | - | Director |
| Mr Mathew Grace | England | 33 years | Feb 2025 | - | Director |
P&L
December 2023turnover
31.7m
-1%
operating profit
7.8m
-8%
gross margin
30.7%
-7.39%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
-4.9m
-0.6%
total assets
270.3m
-0.04%
cash
17m
-0.55%
net assets
Total assets minus all liabilities
st james's oncology spc ltd company details
company number
05113572
Type
Private limited with Share Capital
industry
86900 - Other human health activities
incorporation date
April 2004
age
21
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
catalyst healthcare (leeds) limited (October 2011)
broomco (3467) limited (July 2004)
accountant
-
auditor
JOHNSTON CARMICHAEL
address
c/o albany spc services ltd, 3rd floor, manchester, M1 4HB
Bank
BANK OF SCOTLAND
Legal Advisor
STEPHENSON HARWOOD LLP
st james's oncology spc ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to st james's oncology spc ltd.
st james's oncology spc ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ST JAMES'S ONCOLOGY SPC LTD. This can take several minutes, an email will notify you when this has completed.
st james's oncology spc ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
